Logo image
Back
Less invasive ventricular reconstruction for ischaemic heart failure
Journal article   Open access   Peer reviewed

Less invasive ventricular reconstruction for ischaemic heart failure

Patrick Klein, Stefan D Anker, Andrew Wechsler, Ivo Skalsky, Petr Neuzil, Lon S Annest, Mauro Bifi, Theresa McDonagh, Christian Frerker, Tobias Schmidt, …
European journal of heart failure, v 21(12), pp 1638-1650
Dec 2019
DOI: https://doi.org/10.1002/ejhf.1669
PMID: 31797492
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1002/ejhf.1669View
Published, Version of Record (VoR)CC BY-NC V4.0,  Open

Abstract

Cardiac Surgical Procedures - instrumentation Equipment Design Female Follow-Up Studies Heart Failure - etiology Heart Failure - physiopathology Heart Failure - surgery Heart Ventricles - diagnostic imaging Heart Ventricles - physiopathology Heart Ventricles - surgery Humans Male Middle Aged Myocardial Ischemia - complications Myocardial Ischemia - physiopathology Prospective Studies Quality of Life Stroke Volume - physiology Treatment Outcome Ventricular Function, Left - physiology Ventricular Remodeling
Surgical ventricular reconstruction to remodel, reshape, and reduce ventricular volume is an effective therapy in selected patients with chronic heart failure (HF) of ischaemic aetiology. The BioVentrix Revivent TC System offers efficacy comparable to conventional surgical ventricular reconstruction and is less invasive utilizing micro-anchor pairs to exclude scarred myocardium on the beating heart. Here, we present 12-months follow-up data of an international multicenter study. Patients were considered eligible for the procedure when they presented with symptomatic HF [New York Heart Association (NYHA) class ≥II], left ventricular (LV) dilatation and dysfunction caused by myocardial infarction, and akinetic and/or dyskinetic transmural scarred myocardium located in the anteroseptal, anterolateral, and/or apical regions. A total of 89 patients were enrolled and 86 patients were successfully treated (97%). At 12 months, a significant improvement in LV ejection fraction (29 ± 8% vs. 34 ± 9%, P < 0.005) and a reduction of LV volumes was observed (LV end-systolic and end-diastolic volume index both decreased: 74 ± 28 mL/m vs. 54 ± 23 mL/m , P < 0.001; and 106 ± 33 mL/m vs. 80 ± 26 mL/m , respectively, P < 0.0001). Four patients (4.5%) died in hospital and survival at 12 months was 90.6%. At baseline, 59% of HF patients were in NYHA class III compared with 22% at 12-month follow-up. Improvements in quality of life measures (Minnesota Living with Heart Failure Questionnaire 39 vs. 26 points, P < 0.001) and 6-min walking test distance (363 m vs. 416 m, P = <0.001) were also significant. Treatment with the Revivent TC System in patients with symptomatic HF results in significant and sustained reduction of LV volumes and improvement of LV function, symptoms, and quality of life.

Metrics

9 Record Views
50 citations in Web of Science
49 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Cardiac & Cardiovascular Systems
Logo image